These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29100032)

  • 1. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
    Fletcher EAK; Eltahir M; Lindqvist F; Rieth J; Törnqvist G; Leja-Jarblad J; Mangsbo SM
    Int Immunopharmacol; 2018 Jan; 54():1-11. PubMed ID: 29100032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The blood endothelial cell chamber - An innovative system to study immune responses in drug development.
    Stančič B; Qvarfordt B; Berglund MM; Brenden N; Sydow Bäckman M; Fransson M; Nordling S; Magnusson PU
    Int Immunopharmacol; 2021 Jan; 90():107237. PubMed ID: 33310662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
    Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
    J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.
    Alakhras NS; Qiu J; Rocha GV; Witcher DR; Koester A; You J; Schaer DA; Holmgaard RB; Driscoll K; Willy JA; Malherbe LP
    MAbs; 2018; 10(6):913-921. PubMed ID: 29953319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
    Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
    Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
    Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
    J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies.
    Madsen NH; Gad M; Larsen J
    J Immunol Methods; 2022 Mar; 502():113231. PubMed ID: 35122772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
    Vessillier S; Fort M; O'Donnell L; Hinton H; Nadwodny K; Piccotti J; Rigsby P; Staflin K; Stebbings R; Mekala D; Willingham A; Wolf B;
    Cytokine X; 2020 Dec; 2(4):100042. PubMed ID: 33458650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.
    Walker MR; Makropoulos DA; Achuthanandam R; Van Arsdell S; Bugelski PJ
    Int Immunopharmacol; 2011 Nov; 11(11):1697-705. PubMed ID: 21689786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
    Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
    Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
    Poirier N; Mary C; Le Bas-Bernardet S; Daguin V; Belarif L; Chevalier M; Hervouet J; Minault D; Ville S; Charpy V; Blancho G; Vanhove B
    MAbs; 2014; 6(3):697-707. PubMed ID: 24598534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is an in vitro whole blood cytokine assay useful to detect the potential risk of severe infusion reaction of monoclonal antibody pharmaceuticals?
    Iwata Y; Harada A; Hara T; Kubo C; Inoue T; Tabo M; Ploix C; Manigold T; Hinton H; Mishima M
    J Toxicol Sci; 2016; 41(4):523-31. PubMed ID: 27432238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
    Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
    Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
    Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
    Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.
    Findlay L; Sharp G; Fox B; Ball C; Robinson CJ; Bird C; Stebbings R; Eastwood D; Wadhwa M; Poole S; Thorpe R; Thorpe SJ
    Cytokine; 2011 Jul; 55(1):141-51. PubMed ID: 21493088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm.
    Panoskaltsis N; McCarthy NE; Stagg AJ; Mummery CJ; Husni M; Arebi N; Greenstein D; Price CL; Al-Hassi HO; Koutinas M; Mantalaris A; Knight SC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1127-1142. PubMed ID: 33033851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model.
    Weißmüller S; Kronhart S; Kreuz D; Schnierle B; Kalinke U; Kirberg J; Hanschmann KM; Waibler Z
    PLoS One; 2016; 11(3):e0149093. PubMed ID: 26959227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.